AbbVie Inc

Defitelio could help Jazz Pharmaceuticals become a prominent player not only in the treatment but also in the prevention of post-HSCT complications.

Jazz Pharmaceuticals (JAZZ) expects quarterly variability in Defitelio sales as the drug targets hepatic veno-occlusive disease (or VOD), an ultra-rare condition.

Allergan’s (AGN) international business includes total revenues from the sales of branded products as well as aesthetics products outside the US markets.

For 2Q17, Jazz Pharmaceuticals (JAZZ) reported revenues close to $394 million, which represented a YoY growth of ~3% and sequential growth ~5%.

AbbVie (ABBV) recorded a 12.0% rise in net revenue for 2016, mainly driven by Humira and Imbruvica.

In December 2016, the European Commission granted Venclyxto conditional marketing approval for the treatment of CLL in the presence of 17p deletion or TP53 mutation.

ABBVie anticipates upadacitinib to be commercialized by 2019. If approved, AbbVie’s upadacitinib will directly compete with Pfizer’s (PFE) Xeljanz.

In 2Q17, AbbVie’s (ABBV) Imbruvica generated revenues of around $626.0 million, which reflected a ~43.0% rise YoY and a ~14.0% rise QoQ.

The sector has seen the weakest growth in its top and bottom lines due to uncertainty in terms of sector reforms.

In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth.

If we compare the performances of the defensive sectors, we can see that their YTD performance and one-year performances have been reasonably uniform with the exception of the energy and telecom sectors.

AbbVie (ABBV) has a focused immunology pipeline in order to address various dermatologic and gastrointestinal conditions.

In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.

Johnson & Johnson’s business includes three segments: Pharmaceuticals, Consumer, and Medical Devices.

In 2016, Novartis’s (NVS) Cosentyx surpassed its closest competitor, Eli Lilly’s (LLY) Taltz, in number of total weekly prescriptions in the US market.

Merck (MRK) reported growth of 1% to $39.8 billion in its 2016 revenues as compared to $39.5 billion in 2015.

On October 26, 2016, AstraZeneca (AZN) announced that Lynparza managed to demonstrate a superior clinical profile in the Phase 3 SOLO-2 trial.

Amgen (AMGN) launched Enbrel in the US in 1998. It became a major success for Amgen in no time and recorded $5.4 billion sales in 2015.

With the loss of patent protection for its flagship drug, Lipitor, Pfizer’s revenue fell to $48.8 billion in 2015, compared to $67 billion in 2010.

AbbVie’s (ABBV) Venclexta has been granted FDA breakthrough therapy designation as a first line therapy for patients with acute myeloid leukemia who are ineligible for high-dose chemotherapy.

AbbVie (ABBV) has completed enrollment in its Phase 3 pivotal trials testing investigational therapy risankizumab as a treatment option for psoriasis.

AbbVie (ABBV) and Neurocrine Biosciences (NBIX) have completed two phase 3 trials to evaluate the efficacy and safety of Elagolix as a treatment option for reducing pain associated with endometriosis as compared to a placebo.

Gilead Sciences (GILD) is the leading biotechnology player in the global HIV market.

On September 13, 2015, Pfizer (PFE) completed its acquisition of Hospira for $17 billion.

Wall Street analysts expect Enbrel to earn $3 billion and $2.5 billion from the sale outside US and Canada in fiscal 2016 and 2017, respectively.

Currently being tested in six Phase 3 trials, ABT-494 is expected to be a significant improvement in the standard of care for rheumatoid arthritis.

AbbVie (ABBV) expects its investigational drug Risankizumab to be a transformative therapy for psoriasis.

Regeneron’s (REGN) robust pipeline consists of 13 molecules in various phases of development. Sarilumab is under review with the FDA.

AbbVie believes that the Market has misunderstood the growth potential of Rova-T, which is expected to earn $1.5 billion–$2 billion in peak sales even under extremely conservative assumptions.

AbbVie project that Rova-T, a DLL3-targeted antibody conjugate acquired through the acquisition of Stemcentrx, will earn $5 billion in peak sales.

AbbVie hopes to position Imbruvica as a therapy for multiple indications: follicular lymphoma, solid tumor, and diffuse large B-cell lymphoma, among others.

Now in its phase-1 clinical trial, AbbVie’s PF-06647020, an ADC targeting protein kinase 7 could become a major therapy for advanced solid tumors.

Trinity is a phase-2 clinical trial that tests the use of Rova-T as a third-line therapy for SCLC (small cell lung cancer).

The acquisition of Stemcentrx has added CSC (cancer stem cell) technology platform to AbbVie’s (ABBV) oncology portfolio.

On April 11, 2016, Venclexta became the first BCL-2 inhibitor therapy to be approved by the FDA for chronic lymphocytic leukemia patients with 17p deletion.

Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. For oncology, its product portfolio includes targeted therapies as well as immunotherapies.

If approved, Elagolix could present fierce competition for existing drugs like Teva Pharmaceuticals’ (TEVA) Aygestin and Astrazeneca’s (AZN) Zoladex.

In the first quarter of 2016, Teva Pharmaceutical Industries (TEVA) launched a new drug, Bendeka, in partnership with Eagle Pharmaceuticals.

On July 1, 2015, Baxter separated its Biosciences division into a new entity named Baxalta in an effort to divest risky segments and streamline operations.

In addition to its Oncology and Immunology segments, AbbVie is focused on launching innovative therapies in its Virology, Neurology, and Women’s Health segments.

Since 2013, Abbott Laboratories has generated revenues from a diversified healthcare business spanning across geographies and four primary segments.

AbbVie (ABBV) has continued to improve its operational efficiency, which is expected to result in a net profit margin of 29.8%, a YoY increase of 6.3%. In 3Q15, AbbVie realized a net proft margin of 30.4%.

Revlimid (lenalidomide) is one of Celgene’s (CELG) main revenue drivers. It had revenues of $1.4 billion in 3Q15, excluding the adverse impact of foreign exchange fluctuations.

In partnership with Bristol-Myers Squibb, AbbVie is exploring elotuzumab to treat relapsed refractory multiple myeloma. The drug also received a breakthrough therapy designation from the FDA on May 19, 2014.

Inorganic growth through acquisitions has led to the expansion of Abbott Laboratories across geographies and to the broadening of its product portfolio.

Abbott Laboratories operates across more than 150 countries, employs over 73,000 people, and is the global leader in the nutrition subsector.

The FDA has scheduled the Prescription Drug User Fee Act (or PDUFA) date for Merck’s new hepatitis C combination therapy for January 28, 2016.

In 3Q15, Celgene had a strong inflammation and immunology pipeline. The company witnessed the progress of its key investigational drug GED-0301.

In 3Q15, Biogen saw several positive developments for the drugs developed under its various collaborative arrangements.

Alexion Pharmaceuticals is actively involved in expanding the approved labels for its flagship product Soliris.